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The Current Therapy for Mitral Regurgitation
Blase A. Carabello, MD
Houston, Texas
In addressing the current therapy for mitral regurgitation (MR), it is useful to distinguish primary MR from
secondary (functional) MR. In primary MR, abnormalities of one or more of the components of the mitral
valve cause it to leak, imparting a volume overload on the left ventricle (LV). Severe prolonged primary MR
leads to LV remodeling, myocardial dysfunction, heart failure, and death. Correction of MR, preferably by
valve repair rather than replacement, is curative. Severe MR by itself is considered an indication for repair
in many centers, and mitral surgery (repair or replacement) should take place when even mild symptoms
appear or when ejection fraction approaches 0.60 or end systolic dimension approaches 40 mm. In second-
ary MR, myocardial damage from infarction or cardiomyopathy produces papillary muscle displacement and
annular dilatation, causing a normal valve to leak. Because the MR in this case is not the primary problem,
the indications for mitral valve intervention are less certain and considerably more data are needed to aid
us in selecting the most appropriate patients for surgical therapy. Percutaneous therapies for both primary
and secondary MR have generated much interest, and many different percutaneous technologies are being
developed. Future data from randomized trials will help clarify when and in whom these therapies are
applicable. (J Am Coll Cardiol 2008;52:319–26) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.084P
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rn addressing the modern therapy for mitral regurgitation
MR), it is important to distinguish between primary and
econdary (functional) MR. In primary MR there is
erangement of one or more components of the mitral
alve itself, permitting backflow, causing left ventricular
LV) volume overload. If this overload is severe enough
nd prolonged enough, it results in LV remodeling,
ysfunction, pulmonary hypertension, heart failure, and
ventually death. Correction of primary MR in a timely
ashion reverses these consequences; thus, there is an
nchallenged cause-and-effect relationship between the
rimary MR and its effects on the LV. It is the abnormal
alve that makes the heart sick. Conversely, in secondary
R the mitral valve itself is usually normal. However an
V, previously damaged by coronary artery disease and
yocardial infarction or by dilated cardiomyopathy, de-
elops papillary muscle displacement and annular dilata-
ion, causing the mitral valve to leak. It is a damaged LV
hat causes the valve’s malfunction. Because this is
rimarily a ventricular problem, it is less obvious that
orrecting the MR by itself will be curative or even
eneficial. Thus, although the treatment for primary MR
s relatively straightforward, the therapy for secondary
R is considerably more controversial.
rom the Department of Medicine, Baylor College of Medicine, and the VeteransM
ffairs Medical Center, Houston, Texas.
Manuscript received January 24, 2008; accepted February 13, 2008.rimary MR
athophysiology
itral regurgitation imposes a pure volume overload on the
V. In almost all other volume overloads, the excess volume
umped by the LV is ejected into the aorta, where it widens
ulse pressure, in turn increasing systolic pressure. Thus
ost volume overloads, such as anemia, aortic regurgitation,
nd so on, are actually combined pressure and volume
verloads. On the other hand, the extra volume ejected from
he LV in MR enters the left atrium and systolic blood
ressure is not usually elevated. In fact average systolic
ressure in severe MR is about 110 mm Hg, compared with
bout 150 mm Hg for aortic regurgitation (1). Indeed when
oad was compared between mitral and aortic regurgitation
reload was increased, as would be expected for volume
verload pathophysiology (1). However, afterload was nor-
al in MR but greatly increased in aortic regurgitation. It is
enerally agreed that LV loading represents the mechanical
ignals that orchestrate LV remodeling. The unique loading
onditions of MR generate a unique pattern of remodeling,
ith the largest radius-to-thickness ratio and the smallest
ass-to-volume ratio of the 4 left-sided valve lesions (2).
his pattern of remodeling is both adaptive and maladap-
ive. Increased LV volume allows total stroke volume to
ncrease, in turn increasing forward stroke volume, compen-
ating for the volume lost to regurgitation. In addition the
elatively thin LV wall enhances diastolic filling. Indeed
R is one of the very few cardiac diseases in which diastolic
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Current Therapy for MR July 29, 2008:319–26function is supernormal (3,4).
However, the increased radius-
to-thickness ratio also has its
downside. Recall that wall stress
()  p  r/2h where p  LV
pressure, r LV radius, and h
LV thickness. Although MR is
often viewed as a lesion that un-
loads the LV by creating a sec-
ond pathway for ejection, in fact
the remodeling pattern, by in-
creasing r/h, may actually in-
crease afterload. Only in acute
R is afterload actually decreased; in chronic compensated
R afterload is normal, and in chronic decompensated MR
fterload may actually be greater than normal (5).
The mechanism by which hypertrophy develops in MR
lso seems to be unique. It is well known that myocardial
roteins are constantly turning over. For cardiac mass to
emain constant, the rates of protein synthesis (Ks) and that
f protein degradation (Kd) must also remain constant. For
ypertrophy (increased mass) to occur, Ks must exceed Kd
ither because Ks increases or because Kd decreases. In
ressure overload, hypertrophy develops from increased Ks
s one might expect (6,7). However, in MR, hypertrophy
eems to occur from a decrease in Kd because no increase in
ynthesis rate has been detected (6,8) (Fig. 1).
V dysfunction in MR. Although MR may be tolerated
or a long time in some patients, in others, progression to
eart failure with muscle dysfunction may be more rapid (9).
his transition to heart failure is paralleled by myocyte
ysfunction and sympathetic activation (10–12). In general,
egurgitant fractions (RFs) of 0.40 seem to be tolerated
ndefinitely in both the experimental animal and in humans,
hereas RFs exceeding 0.50 usually leads to heart failure.
yocytes and/or myocardial strips taken from subjects in
eart failure show loss of contractile elements and abnor-
alities in calcium handling (13,14). Both correction of the
olume overload and beta blockade (at least in animals) can
mprove contractility at the chamber and sarcomere levels,
uggesting that sympathetic overactivity as well as the
olume overload itself are implicated in the pathophysiology
f the LV dysfunction (12,15,16). Indeed in humans, the
ympathetic nervous system is activated in this disease and
ctivity correlates with the amount of LV dysfunction
resent (11). Thus reduction in the amount of MR present
nd/or beta blockade might serve as therapeutic targets.
edical therapy. As noted in the previous text, regurgitant
ractions of 0.4 seem to be tolerated indefinitely. Thus
educing RF medically seems an attractive goal. It is known
hat vasodilators are effective in acute MR in reducing RF
17). This occurs as vasodilators preferentially increase
orward flow while simultaneously reducing regurgitant
ow, partially by reducing aortic impedance and partially by
educing regurgitant orifice area. However, medical thera-
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
LV  left ventricle/
ventricular
MR  mitral regurgitation
MVR  mitral valve
replacement
MVRe  mitral valve repair
RF  regurgitant fractionies for chronic MR have produced disappointing and sonflicting results. Studies of angiotensin-converting en-
yme inhibitorshave been inconclusive in the therapy of MR
n humans (18–21), in naturally occurring MR in the dog
22,23), and in experimental canine MR (24). Likewise,
ngiotensin receptor blockers also have produced uneven
esults (25,26), although no large randomized trials have
een performed with either angiotensin-converting enzyme
nhibitors or angiotensin receptor blockers. Thus, these
herapies are not recommended for the prevention of LV
ysfunction in MR. However, they are of course recom-
ended for the therapy of heart failure whether or not MR
s present.
Beta-blockers have been shown effective in reversing the
V dysfunction caused by experimental MR where the
echanism is one of restoration of sarcomere structure and
unction (12). Whether these results apply to humans awaits
andomized trials for a definitive answer.
Although the average systolic blood pressure for MR
atients available from the literature is about 110 mm Hg,
Figure 1 Protein Synthesis
Myosin heavy chain (MHC) synthesis rate (Ks) and degradation rate (Kd) are
shown for dogs with severe mitral regurgitation (MR) at 2 weeks (2W), 4 weeks
(4W), and 3 months (3M) after initiation of the lesion expressed as a percent
of the total pool (A) and as mg/day (B). Because left ventricular mass
increased by 30% and no increase in Ks could be detected, a decrease in Kd is
inferred. Reprinted with permission from Matsuo et al. (8).ome patients with this lesion are hypertensive. Because
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July 29, 2008:319–26 Current Therapy for MRypertension increases the pressure gradient between the
eft atrium (LA) and LV, it also increases regurgitant
olume. Obviously hypertension imparts huge health risks
f its own. For these reasons, patients with MR and
ypertension should be treated to lower their blood pressure
o standard targets using those antihypertensive agents that
ork best for the individual.
urgical Therapy
he basics of MR pathophysiology are noted above. Mitral
egurgitation imparts a volume overload on the LV that
ogether with neurohumoral activation leads to LV remod-
ling and dysfunction. Mitral regurgitation is a mechanical
roblem that can only be corrected with a mechanical
olution, that is, restoration of valve competence, thus
emoving the volume overload and its deleterious conse-
uences. There is near unanimity that mitral valve repair
MVRe) instead of mitral valve replacement (MVR) is the
referred method of MR correction in nonrheumatic valves
27–31). Sparing even the posterior chordae is superior to
otal ablation of the mitral apparatus (29), and most reports
how a lower operative mortality with MVRe compared
ith MVR and better long-term survival (Fig. 2) (30). Thus
t is unfortunate that in developed countries where mitral
alve prolapse and myxomatous degeneration are the emi-
ently repairable causes of MR that only one-half of such
alves are actually repaired (27).
It is important to recognize that the mitral valve is an
Figure 2 Survival in MR
Survival after mitral valve repair (MVP) is compared with that after mitral valve
replacement (MVR) for propensity-matched groups. Patients undergoing MVP
had better survival. MR  mitral regurgitation. Reprinted with permission from
Jokinen et al. (30).mportant component of the LV, serving a major role in LVunction by helping to maintain LV shape and chamber
ontractility. Destruction of the mitral valve apparatus at the
ime of MVR causes an immediate decrease in chamber
ontractility and an increase in afterload as the radius term in
he Laplace equation increases (32,33). It was once believed
hat ejection fraction decreased after correction of MR because
urgery obliterated the low impedance pathway for ejection
nto the LA, in turn increasing LV afterload. In fact MVRe
lso removes the low-impedance LA ejection pathway but
auses only minor changes in ejection fraction, indicating that
he large decrease in ejection fraction after MVR is caused by
estruction in the mitral valve apparatus instead of its effect on
jection into the LA (33–35) (Fig. 3).
An MVR during which some or all of the chordal
ttachments between the papillary muscles and valve leaflets
re maintained helps to preserve LV function compared
ith MVR (34,35) and improves exercise capacity (34).
urther, one study indicates that replacement with chordal
reservation improves mortality and late outcome compared
ith MVR alone (29).
iming of Surgery
atients with mild to moderate disease. Patients with less
han severe MR, that is, those with an RF of 0.5, those
ith a regurgitant volume of 60 ml/beat, and those with
regurgitant orifice area of 0.4 cm2, tolerate MR for long
eriods as long as the disease does not worsen. Currently
urgery is not indicated in such patients. Instead they are
bserved periodically for worsening of disease, the onset of
ymptoms, and the occurrence of LV dysfunction.
atients with asymptomatic severe MR with normal LV
unction. Patients without symptoms of dyspnea, orthop-
ea, or paroxysmal nocturnal dyspnea who have normal LV
unction have an excellent short-term prognosis, and many
Figure 3 Results of Repair Versus Replacement
Ejection fraction before and after mitral valve surgery with preservation of the
mitral valve apparatus (solid circles) is compared with ejection fraction before
and after mitral valve surgery with removal or the apparatus (open squares).
Reprinted with permission from Rozich et al. (33).
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Current Therapy for MR July 29, 2008:319–26xperts would observe such patients until early symptoms or
vidence of LV function develops. However, patients with
evere MR are likely to develop symptoms, LV dysfunction,
r atrial fibrillation within a relatively short period of time (2
o 3 years), especially in the face of a flail leaflet (9). Thus
any centers would consider repairing such valves shortly
fter discovery. Repair offers low mortality in such patients
1% in experienced centers [31]) and reduces the risk of
nwanted sequelae and the need for close longitudinal
ollow-up for the onset of symptoms or LV dysfunction.
ndeed the recent American Heart Association/American
ollege of Cardiology guidelines on valvular heart disease
ecommend surgery for such patients at a IIa level (most
ould favor surgery) where there is a 90% likelihood the
alve can be repaired (27). However, as the recommendation
mplies, MVR (instead of repair) would be most unfortu-
ate in such patients because a patient who did not need
urgery at that time would receive a prosthetic valve and its
ttendant risks.
ymptomatic patients with normal LV function. Al-
hough ventricular function is a key determinant of outcome
n all valvular heart disease, symptoms have a major impact
n prognosis even when LV function is normal (Fig. 4) (36).
hus surgery, preferably MVRe, should be performed once
ven mild symptoms develop (27).
symptomatic patients with LV dysfunction. Although
V function may improve after MVRe this is by no means
ertain, and while sophisticated measures of LV function are
vailable, they are impractical for daily use. However, when
jection falls toward 0.60 or when end-systolic dimension
pproaches 40 mm, post-operative outcome worsens, sug-
esting that these are fairly reliable markers for clinically
mportant LV dysfunction (27,37,38). Thus, irrespective of
ymptomatic status, surgery, preferably MVRe, should be
Figure 4 Outcome and Symptoms
Survival of patients after surgery for MR with normal ejection fraction (EF) (left) an
functional class had a large impact on survival in both groups. MR  mitral regerformed once these objective benchmarks for LV dys-
unction are reached.
lderly patients with MR. In many earlier reports, ad-
anced age had a major negative impact on the outcome of
itral valve surgery (28,37). Patients age 75 years under-
oing MVR had an operative mortality as high as 31%.
owever, more recent studies in the elderly show a marked
mprovement in operative mortality and late survival, espe-
ially when MVRe is used (39,40). Although it seems
nwise to recommend surgery to asymptomatic elderly MR
atients who have normal LV function, surgery should not
e withheld in older symptomatic patients, especially when
VRe is likely.
atients with far advanced disease. When it was believed
hat closure of the LA ejection pathway obligated an
ncrease in afterload and a decrease in ejection performance,
atients with primary MR and low ejection fraction were
onsidered inoperable. It was reasoned that increased after-
oad would lead to a prohibitive further decline in LV
unction. It is now known that although prognosis is
educed in such patients, MVRe can improve symptoms and
s relatively well tolerated (41). It is assumed that MVR,
hich by itself worsens LV function, would not be effective
n such patients, although data from randomized trials of
VRe versus MVR are lacking.
econdary MR
athophysiology
s noted in the previous text, the pathophysiology of
rimary MR is relatively straightforward. The incompetent
alve causes an LV volume overload, leading to ventricular
emodeling, myocardial dysfunction, and heart failure. Cor-
ection of the MR and of the volume overload in a timely
reduced EF (right) are shown. Advanced New York Heart Association (NYHA)
tion; NS  nonsignificant. Reprinted with permission from Tribouilloy et al. (36).d with
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July 29, 2008:319–26 Current Therapy for MRashion leads to reversal of its pathophysiological conse-
uences. However, the pathophysiology of secondary MR is
uch more complex. Here myocardial damage either
hrough one or more myocardial infarctions or from dilated
ardiomyopathy has caused an anatomically normal valve to
eak. Even if the MR is corrected, the underlying muscle
isease will still exist. This fact must contribute to worsened
rognosis of secondary MR (42–44). Thus the advantages
f correction of secondary MR are less clear. Is the MR a
elatively innocuous bystander like the fever in infection, or
s the MR a major contributor to the negative prognosis of
econdary MR, a prognosis that is in fact much worse than
hat of primary MR?
It is clear that the presence of MR in ischemic and dilated
ardiomyopathies worsens prognosis (Fig. 5) (42). How-
ver, these data have 2 potentially very different interpreta-
ions. On one hand, it may be that the volume overload
reated by the MR adds a greater pathologic burden to an
lready adverse condition. On the other hand, it may simply
e that poorer ventricular function is the cause of the poorer
rognosis and that the MR simply is an indicator of the
oorer LV function. The issue is central to the therapy for
he condition. If secondary MR is a cause for worsened
rognosis, it should represent a reasonable target for ther-
py. However, if secondary MR is simply a byproduct of
isturbed LV geometry and function, correction of second-
ry MR may have little impact on outcome.
edical Therapy
hereas there are no conclusive data showing that medical
herapy is effective in patients with primary MR, it must be
ecognized that almost all patients with secondary MR have
eart failure. As such, patients with secondary MR should
e treated with standard heart failure therapy, which typi-
Figure 5 Functional MR and Survival in CHF
Survival for patients with heart failure is shown for varying severities of MR. Patien
had a significantly worse outcome. CHF  congestive heart failure; MR  mitral really includes angiotensin-converting enzyme inhibitors (or
ngiotensin receptor blockers), beta-blockers, diuretics, and
ldosterone antagonists. Although these agents may alter
egurgitant volume, their major thrust is at the antecedent
eart failure.
esynchronization Therapy
ecause wall motion abnormalities are often part of the
ause of secondary MR, it is logical that electrical cardiac
esynchronization therapy (CRT) would have a therapeutic
ole here, and indeed it does. In selected patients, CRT
educes the amount of MR and improves cardiac output and
ymptomatic status (45).
utcome of Correction of Secondary MR
nce the concept that correction of MR had to increase
fterload and decrease ejection fraction was dispelled, pa-
ients with MR and very low ejection fraction from cardio-
yopathy (ischemic or idiopathic) could be considered for
urgery. Bach and Bolling (46) reported on partial correc-
ion of secondary MR using a restrictive annuloplasty ring.
y reducing annular diameter, this simple procedure signif-
cantly reduced the amount of MR present and was well
olerated with an operative mortality of 5%. One year
ater, 75% of the patients were still alive and LV volumes
ecreased significantly, likely reducing afterload by decreas-
ng the radius term in the Laplace equation, the mechanism
y which there was a modest increase in LV ejection
raction. Others have shown similar results (47). In the
corn trial, patients with secondary MR were randomized
o receive either MVRe alone or MVRe plus an external
estraint device. Importantly, substantial reverse remodeling
ccurred in the MVRe (48) only group, as it has in other
eports (49).
moderate to severe MR
tion. Reprinted with permission from Trichon et al. (42).ts with
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Current Therapy for MR July 29, 2008:319–26As yet there is no proof that such surgery prolongs life. In
act in nonrandomized data from the Bolling group, there
as no evidence of improved survival (44). Further, some
ave questioned whether surgery in ischemic MR improves
urvival and/or long-term quality of life (Fig. 6) (50). It is
lear from the disparate results published in the literature
hat a large randomized trial is needed to identify the proper
ole of MVR and MVRe in the treatment of patients with
econdary MR.
In coronary revascularization alone versus combined re-
ascularization and mitral surgery, it is general practice to
orrect severe MR during coronary artery bypass graft
urgery. However, even this mode of therapy has been
uestioned. Diodato et al. (51) found no increased risk to
dding MVRe, but neither did they find long-term benefit,
nd others have raised the same issue (52). Although it seems
lear that the presence of even moderate MR worsens prog-
osis for those undergoing coronary artery bypass graft surgery
53), there is a clear divergence of opinion about whether MR
Figure 6 Results of Mitral Surgery in CHF
Unadjusted (A) and propensity-adjusted (B) survival of patients with secondary
MR are shown and separated into groups of coronary artery bypass graft
(CABG) surgery alone or CABG surgery plus mitral annuloplasty. No difference
in survival was detected. Reprinted with permission from Mihaljevic et al. (50).
MV  mitral valve; other abbreviations as in Figure 5.hould be corrected during revascularization (54,55).ercutaneous Therapies
he potential for mechanical relief of MR without surgery
as ignited much interest, spurring the advance of several
ew technologies. Two basic types of interventions are
eing developed. One group of interventions apposes the
enter of the 2 mitral leaflets, producing a double-barrel
pening and reducing or eliminating MR while avoiding
itral stenosis (56). A second group of interventions utilizes
he close proximity of the mitral annulus to the coronary
inus. By inserting devices into the coronary sinus that
echanically alter its shape, the shape of the annulus is also
ltered, in turn helping to restore mitral competence
57,58). Early experience shows that these devices can be
ffective. However, the role in our armamentarium for
reating MR awaits development of more data.
ummary
rimary MR imparts a volume overload on the LV, leading
o LV eccentric hypertrophy and remodeling. Although this
emodeling is essential to compensating forward stroke
olume, it eventually leads to myocardial systolic dysfunc-
ion and increased afterload despite the tendency of MR to
nload the LV. Current medical therapy is not effective in
reating the condition. On the other hand, timely MVRe
everses or prevents LV dysfunction and is the preferred
ethod of therapy. Unfortunately this procedure is still
nderutilized in the U.S.
On the other hand, secondary MR stems from an
lready-damaged LV. Although surgical mortality has de-
lined for this entity (59), long-term outcome is still poor,
resumably because correction of the MR cannot by itself
orrect the underlying muscle dysfunction. Best manage-
ent for secondary MR includes standard therapy for heart
ailure and CRT in selected patients. There must surely be
role for surgery and possibly for percutaneous devices.
owever, their exact roles have yet to be determined, and
ntil more data are available, equipoise should hold sway in
ur thinking about these therapies.
eprint requests and correspondence: Dr. Blase A. Carabello,
eterans Affairs Medical Center, Medical Service (111), 2002 Hol-
ombe Boulevard, Houston, Texas 77030. E-mail: blaseanthony.
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